Eli Lilly lifts full-year revenue outlook as GLP-1 sales surge, shares jump to record
Lilly raised guidance on booming tirzepatide demand for obesity and diabetes, though deal-related charges trimmed the profit view.
Reuters · +14 outlets
Big Pharma posts record quarterly revenue despite Trump administration pricing pressure
Strong GLP-1 and oncology sales outweighed political pressure on drug prices, with pharma seeking friends in both parties ahead of midterms.
Bloomberg · +9 outlets
Hengrui Pharma signs deal worth up to $2.6B with Novo Nordisk for oral GLP-1 drug
The licensing pact adds another oral GLP-1 candidate to Novo's pipeline as competition in the obesity market intensifies.
scanx.trade · +6 outlets
India's NPPA sets new MRPs for 543 cancer brands, with cuts up to 89% but no relief for 25% of drugs
Experts warn markups of up to 700% persist on patented therapies and call for compulsory licensing as affordability concerns mount.
Pragativadi · +14 outlets
HHS to allow compounders to make six unapproved peptides
The move follows GLP-1 drug shortages and reshapes the rules for compounded versions of popular peptides.
BioPharma Dive · +13 outlets
INOVIO wins FDA accelerated approval for VOCERYQ
The accelerated nod gives INOVIO its first approved product and a commercial foothold.
Stock Titan · +8 outlets
AbbVie's Skyrizi and Rinvoq dominate Q3 as analysts question what comes next
The immunology duo drove results, but attention turns to AbbVie's pipeline beyond its two biggest growth drivers.
Fierce Pharma · +1 outlets
Ascletis reports positive Phase II results for oral GLP-1 ASC30 in diabetes
The oral candidate delivered up to 1.7% HbA1c reduction as global obesity trials advance.
Trend Hunter · +4 outlets
Vertex Pharmaceuticals faces key FDA test after RAINIER data
The regulatory decision is a pivotal catalyst for Vertex's stock and its broader pipeline ambitions.
ad-hoc-news.de
Agios sickle cell drug FDA review extended to Feb. 1, 2027
The three-month delay pushes the decision on Agios's sickle cell candidate into 2027.
Stock Titan · +6 outlets
Lilly's triple agonist candidate shows double Ozempic's weight loss in race for next-gen obesity drugs
The next-generation obesity pipeline intensifies as companies pursue multi-agonist mechanisms.
아시아경제 · +14 outlets
FDA approves Ilumya for adults with active psoriatic arthritis
The expanded label broadens Sun Pharma's Ilumya into psoriatic arthritis treatment.
Pharmaceutical Executive · +13 outlets
Alzheimer's drug misses main trial goal and developer plans to halt development
The failed endpoint ends the program's path to regulators.
Stock Titan · +2 outlets
Novo Nordisk stock narrative shifts on new obesity drug data
New data prompted investors to reassess the competitive position of Novo's obesity franchise.
Simply Wall St · +14 outlets
Oncolytics Biotech GOBLET data show durable anal-cancer responses
The pelvic-anal cancer results support continued development of the company's oncolytic virus therapy.
ad-hoc-news.de · +5 outlets
West Pharma Q3 earnings highlight margin expansion and GLP-1 growth
The injectable-device supplier showed it is more than a simple GLP-1 proxy as margins improved.
Simply Wall St · +14 outlets
PhRMA challenges CMS GLOBE model in new Medicare Part B drug pricing fight
The dispute centers on a new federal model for how Part B drugs are priced and paid for.
RamaOnHealthcare
Viking Therapeutics Q3 misses estimates amid rising clinical expenses
Investors weigh rising trial costs against the timeline for a potential 2029 obesity drug launch.
TradingView